Compare Mesoblast Limited (MESO) vs Standard Lithium Ltd (SLI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Standard Lithium Ltd — how do they compare? Mesoblast Limited trades at $16.08 (market cap $2.17B), while Standard Lithium Ltd trades at $2.17 (market cap $523.89M). The key difference: Mesoblast Limited is far larger — about 4.1× Standard Lithium Ltd's market cap, and Mesoblast Limited is trading nearer its 52-week high, Standard Lithium Ltd nearer its low. Which is the better fit depends on your goals.
| MESO | SLI | |
|---|---|---|
Market Cap | $2.17B | $523.89M |
Sector | Technology | Basic Materials |
52-Week High | $20.96 | $5.65 |
52-Week Low | $12.88 | $2.15 |
Enterprise Value | $2.17B | $383.09M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
Standard Lithium (SLI) trades at $2.15, down 4.87% today, reflecting bearish technical signals and negative profitability metrics. The company reported a net loss of $48.40 million for 2025, though it secured a $225 million DOE grant and key construction contracts for its Arkansas lithium project. Analyst consensus remains unanimously bullish with three buy ratings, citing progress toward a final investment decision in 2026.
The investment case hinges on successful project execution, with upside potential from lithium demand and federal funding, but risks include sustained cash burn and delays. The stock's current valuation at 1.52 times book value may attract value investors, yet profitability challenges and bearish technical trends warrant caution amid high operational expenditures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Standard Lithium Ltd
Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →
